Abstract
Background: Obestatin is a novel hormone derived from preproghrelin, which was reported to inhibit appetite and gastric motility. Study Aim: This study aimed to investigate plasma obestatin levels in obese patients with T2D patients, which had not been studied clearly in last researches. Methods: 23 normal weight subjects, 35 obese subjects and 31 obese patients with T2D participated in the study, the body mass index was calculated. Fasting glucose and insulin levels were measured and the homeostasis model assessment of insulin resistance (HOMA-IR) was determined. Plasma obestatin levels were measured with enzyme-linked immune sorbent assay (ELISA). The relationship between plasma obestatin levels and biochemical parameters was also analyzed. Results: Fasting obestatin was significantly lower in obese patients with T2D, comparing to control subjects (mean=6.35 vs12.38ng/ml) and to the non-patients obese group (mean=6.35 vs 7.76 ng/ml). Obestatin levels correlated significantly and negatively with BMI (R=-0. 451; P=0. 01), basal insulin levels (R=-0.737, P<0.0001) and HOMA-IR (R=-0. 764, P<0.0001) in diabetic patients. Conclusion: Our results suggest that obestatin may contribute to body weight regulation, and insulin sensitivity could be affected by obestatin levels.
Highlights
Diabetes is a major health problem which its prevalence has been increasing over the last years [1], Type 2 diabetes (T2D) accounts for 90-95% of diabetes cases, and characterized by insulin resistance, and obesity in most patients [2], and obesity in most patients [3], and the aim of the medical treatment is to decrease insulin resistance and increase beta cell insulin production [4].By using bioinformatics, Zhang et al (2005) identified a 23-amino- acid amidated peptide called obestatin, encoded1874-9445/17 2017 Bentham OpenRelation of Plasma Obestatin Levels with BMIThe Open Public Health Journal, 2017, Volume 10 133 by the same precursor gene of ghrelin [5]
Fasting obestatin was significantly lower in obese patients with T2D, comparing to control subjects and to the non-patients obese group
Our results suggest that obestatin may contribute to body weight regulation, and insulin sensitivity could be affected by obestatin levels
Summary
Diabetes is a major health problem which its prevalence has been increasing over the last years [1], Type 2 diabetes (T2D) accounts for 90-95% of diabetes cases, and characterized by insulin resistance, and obesity in most patients [2], and obesity in most patients [3], and the aim of the medical treatment is to decrease insulin resistance and increase beta cell insulin production [4].By using bioinformatics, Zhang et al (2005) identified a 23-amino- acid amidated peptide called obestatin, encoded1874-9445/17 2017 Bentham OpenRelation of Plasma Obestatin Levels with BMIThe Open Public Health Journal, 2017, Volume 10 133 by the same precursor gene of ghrelin [5]. Relation of Plasma Obestatin Levels with BMI. Whereas ghrelin effects are mainly diabetogenic, obestatin behaves as antidiabetogenic peptide by positively affecting on lipid and glucose metabolism [6]. Obestatin and ghrelin are largely produced throughout the GI tract (like stomach, pancreas and duodenum) with predominant expression in the gastric mucosa [7]. Obestatin is found in the GI tract, within the A-like cells and oxyntic glands of the gastric mucosa. The majority of obestatin found in the crypts of Lieberkuhn and Brunner’s glands, and absence from the colon [8]. Obestatin is a novel hormone derived from preproghrelin, which was reported to inhibit appetite and gastric motility. Study Aim: This study aimed to investigate plasma obestatin levels in obese patients with T2D patients, which had not been studied clearly in last researches
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
